Antihypertensive Medications in Patients with Bradycardia

High-Risk Antihypertensives

Beta-blockers should be avoided in patients with pre-existing bradycardia as they can worsen the condition and lead to severe bradyarrhythmias, according to the American Heart Association 1, 2
All beta-blockers, including cardioselective agents and non-cardioselective agents, carry this risk in patients with bradycardia 1, 3
Non-dihydropyridine calcium channel blockers, such as diltiazem and verapamil, significantly slow sinoatrial and atrioventricular nodal conduction and should be avoided in bradycardia, as recommended by the American College of Cardiology 1, 3

Dihydropyridine calcium channel blockers, such as amlodipine and felodipine, have minimal effects on heart rate and are generally safe in bradycardia, according to the American Heart Association 1, 3, 4
ACE inhibitors and ARBs do not significantly affect heart rate and are suitable alternatives for patients with bradycardia, as recommended by the American College of Cardiology 1, 3
Diuretics, such as hydrochlorothiazide and furosemide, do not directly affect heart rate and can be safely used in patients with bradycardia, according to the American Heart Association 1, 3

Elderly patients are at higher risk for bradycardia with rate-slowing medications due to decreased baroreceptor response, as noted by the American Geriatrics Society 5
Polypharmacy increases the risk of bradycardia, especially when multiple medications with potential bradycardic effects are combined, according to the American Heart Association 5

Monitor heart rate and blood pressure when initiating any antihypertensive therapy in patients with or at risk for bradycardia, as recommended by the American College of Cardiology 4
If a patient with bradycardia requires antihypertensive therapy, start with agents that have minimal effects on heart rate, according to the American Heart Association 6

Beta-blockers, including cardioselective agents, non-cardioselective agents, and combined alpha-beta blockers, should be avoided in patients with bradycardia as they can worsen bradycardia and potentially lead to severe cardiovascular complications, according to the American Heart Association guidelines 7
Non-dihydropyridine calcium channel blockers, such as diltiazem and verapamil, are contraindicated in patients with bradycardia as they significantly slow sinoatrial and atrioventricular nodal conduction, with a high level of evidence from the European Society of Cardiology 7
Central alpha-2 agonists, including clonidine, methyldopa, and guanfacine, can precipitate or exacerbate bradycardia and should be avoided in patients with bradycardia, based on recommendations from the European Heart Journal 8

Dihydropyridine calcium channel blockers, such as amlodipine, felodipine, and nicardipine, have minimal effects on heart rate and are generally safe options for patients with bradycardia, according to the American College of Cardiology guidelines 9
Diuretics, including thiazides and loop diuretics, do not directly affect heart rate and can be safely used in patients with bradycardia, with a moderate level of evidence from the Hypertension journal 9
Direct vasodilators like hydralazine may be considered as they can actually increase heart rate through reflex tachycardia, potentially beneficial in patients with bradycardia, based on recommendations from the Hypertension journal 9

Elderly patients are at higher risk for bradycardia with rate-slowing medications due to decreased baroreceptor response, according to the European Heart Journal guidelines 8
Electrolytes and renal function should be monitored regularly, especially if diuretics are used, with a high level of evidence from the European Heart Journal 8

The American Heart Association recommends maintaining a diastolic blood pressure above 60 mmHg, particularly in patients over 60 years of age, to ensure adequate coronary perfusion 10
ACE inhibitors, such as lisinopril, do not affect heart rate and are suitable alternatives for patients with bradycardia, providing a mortality benefit in patients with cardiovascular disease 11, 10
The European Heart Journal suggests that hyperkalemia from ACE inhibitor/HCTZ combination can worsen bradycardia, and recommends checking electrolytes, including potassium levels 12, 13
Assessing volume status is crucial, as overdiuresis can cause hypotension and reflex bradycardia, according to Circulation 11
The target blood pressure should be below 130/80 mmHg, but not at the expense of symptomatic hypotension, as recommended by Circulation 10
A wide pulse pressure, such as 56 mmHg, is a red flag, suggesting arterial stiffness and increasing the risk of end-organ hypoperfusion, according to Circulation 10
Monitoring plan should include checking orthostatic vital signs, monitoring heart rate and BP daily, rechecking electrolytes and renal function, and assessing for symptoms of hypoperfusion, as recommended by European Heart Journal and Circulation 11, 12